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ABSTRACT 
Every year most of the deaths were leaded by cardio and cerebrovascular disorders around the globe. The use of first or second generation thrombolytics may rise several 
side effects like bleeding in biological system at the time of treatment. New generation thrombolytics plays an important role in the treatment of thromboembolic disorders 
which leads to the death. An ideal fibrin specific plasminogen activator, staphylokinase converts a precursor, plasminogen to active enzyme, plasmin to dissolve the blood clot 
during thrombolytic therapy and it also capable to destroy the normal components of haemostatic system which leads to life threatening consequence and also death. Out of 
four different thrombolytics which are available in market like alteplase, reteplase, streptokinase and tenecteplase, streptokinase was widely used drug because of its low 
cost. But, to overcome the hurdles like bleeding and reocculsion efforts have been made to construct the more potent staphylokinase devoid of risk. In this review, progressive 
development on staphylokinase has been discussed. 
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INTRODUCTION 
In  Europe  and  U.S,  most  of  the  deaths  and  disabilities  were 
leaded  by  thrombotic  diseases,  where  a  thrombus  develops  in 
circulatory system can cause vascular blockage [1, 2]. A healthy 
homeostatic  system  extensively  shows  its  action  at  the time  of 
vascular injury to prevent blood loss [3]. Thrombotic disorders like, 
myocardial  infarction,  cerebrovascular  thrombosis,  pulmonary 
embolism  and  deep  venous  thrombolism  are  life-threatening  to 
humans.  Failure  of  human  homeostatic  system  requires  the 
administration  of  artificially  prepared  thrombolytic  agents.  An 
attempt  with  thrombolytic  therapy  for  ischemic  stroke  was 
established with plasmin [4] and streptokinase [5]. 
Plasminogen  activators  (PA)  are  characterized  into  two  types: 
fibrin specific and non fibrin specific. Fibrin specific PA such as 
tissue-type PA (t-PA) or single-chain urokinase PA (scuPA) and 
non  fibrin  specific  PA  such  Streptokinase  (SK)  ,  two-chain 
urokinase-type PA (tcu-PA, urokinase) are in clinical use because 
of its low cost [6]. All these thrombolytics act on thrombus and 
results the degradation of fibrin. 
The  use  of  staphylokinase  in  thrombotic  therapy  had  a  great 
scope to treatment vascular complications, but it was not reached 
at  the  stage  of  medical  practice.  From  last  two  decades  a 
progressive research was going on to hunt the ideal thrombolytic 
drug with minimal risk. So, numerous trails were conducted with 
the various thrombolytic agents but not reached up to the mark 
because of cost and specificity. In this review, different properties 
of staphylokinase, that would appear to have potent thrombolytic 
agent for treatment of cardio and cerebrovascular disorder. 
STROKE 
Every year, approximately 12 million people die of a heart attack 
or  a  stroke.  It  is  not  limited  to  the  poor  as  well  as  rich.  Heart 
attacks and strokes are devoid of sexes. Comparatively women 
have  more  risk.  Heart  gets  oxygenated  blood  through  vessels 
called coronary arteries. When the blood flow to the heart was 
stopped, it leads to the decreased supply of oxygen results the 
damage of its function. If the blockage is sudden and onset, it is 
called “heart attack”, if the blockage is fractional and flow of blood 
to heart was decreased, it can leads to chest pain not permanent 
damage to heart muscles, but it is a threatening sign to the person 
in future he/she could alleged from heart attack. 
REASONS BEHIND HEART ATTACK AND STROKES 
Heart attacks and strokes are mostly triggered by obstruction of 
blood  flow  to  heart  or  brain  because  of  fatty  depositions 
(atherosclerosis) or by the accumulation of blood components on 
the inner walls of the blood vessels (blood clots). This makes the 
flow of blood in vessels was slow and less flexible. So, the blood 
vessels  are  unable  to  supply  the  blood  to  heart  and  brain. 
Atherosclerosis  mainly  caused  by  unhealthy  diet,  smoking, 
drinking and chewing of tobacco related compounds. 
Strokes can cause in two ways. (i) Blood vessel in the brain can 
rupture  and  leads  to  damaging  the  brain  called  intracerebral 
haemorrhage. (ii) Person has a feeble or uneven heartbeat, clot 
formation occur in the heart and pass through the blood vessels to 
the brain. These clots trapped in a narrow brain artery and blood 
flow was blocked to the brain. 
IDEAL FEATURES OF THROMBOLYTIC DRUGS 
  Fibrin specificity 
  Stability 
  Good patency. 
  No reocclusion rate  
  Resistant to plasminogen activator inhibitor-1(PAI-1) 
  Non antigenic  
  Cost effective 
  Easy to Administer 
  Low  frequency  of  systemic  bleeding  and  intracranial 
hemorrhage 
THROMBOLYTIC AGENTS 
Thrombolytics were used to treat different types of venous and 
arterial thromboembolic disorders [7]. These are the plasminogen 
activators  (PA’s)  that  make  use  of  the  vascular  system's  own 
intrinsic thrombo resistance defense mechanism by accelerating 
and amplifying the conversion of an inactive plasminogen to the 
active  plasmin,  a  natural  fibrinolytic  agent,  which  in  turn 
hydrolyzes several key bonds in the fibrin (clot) matrix causing 
dissolution [8]. The detailed mechanism of fibrin specific and non 
fibrin specific thrombolytics were shown in Fig – 1. 
Thrombolytic drugs would have preferably rapid reperfusion can 
establish TIMI grade 3 flow in patients alleged by thrombosis [9, 
10]. These agents would also have extended half-life that permits 
single  bolus  dosing,  facilitate  more  timely  and  problem-free 
administration.  Thrombolytic  agents  can  be  categorized  on  the 
source of the agent, the tendency for enhanced enzymatic activity 
on a fibrin or cell surface or based on the mechanism of action or 
different generations wise. Each of these methods of classification 
is  useful  in  helping  to  characterize  the  diverse  nature  of 
plasminogen activators, but regardless of how one defines these 
agents, they all serve one primary purpose i.e the conversion of 
plasminogen  to  plasmin.  Each  of  these  approved  agents  for Kotra et.al                                                                                                                Mintage journal of Pharmaceutical & Medical Sciencesǀ28-34 
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clinical use has been briefly discussed below with their drawbacks 
also. 
 
 
Fig  1:  Working  mechanism  of  the  non-fibrin  specific 
thrombolytics  and  the  fibrin-specific  thrombolytic  agents. 
The  thickness  of  the  arrow  indicates  the  efficacy  of  the 
action.  The  fibrin-specific  thrombolytic  agents  more 
efficiently dissolve the thrombus than the non fibrin specific 
thrombolytic  agents  (Source  from  Current  Pharmaceutical 
Design, 2006, 12, 849-857). 
UROKINASE 
A 411 amino acid serine protease, Urokinase, the first generation 
molecule is a non fibrin specific thrombolytic agent and also called 
urokinase-type Plasminogen Activator (u-PA) was produced from 
human urine, having the molecular weight of 54 KDa. It consists of 
three domains (a) Carboxyl terminal serine protease domain (b) 
Kringle domain (c) Amino terminal, a growth factor domain [11]. 
Severe side effects were also associated upon the administration 
of  urokinase  to  the  patients  alleged  from  acute  myocardial 
infarction. Due to these reasons FDA detached the Abbokinase® 
(Brand  name  of  urokinase)  from  the  market  because  of  major 
deviation from current good manufacturing procedure. 
STREPTOKINASE 
Wonder drug, Streptokinase is an plasminogen activator produced 
by  various  strains  of  β-hemolytic  Streptococci.  In  1933, 
streptokinase fibrinolytic activity was described [12] and in 1958 it 
was  used  in  the  patients  with  acute  myocardial  infarction  and 
these  results  changed  the  focus  of  treatment.  It  is  a  non-fibrin 
specific  extracellular  enzyme  with  molecular  weight  of  47  kDa 
composed of 414 amino acids, make use of its fibrinolytic action 
activating  the  circulatory  plasminogen  indirectly  [13].  Like 
urokinase,  streptokinase  has  three  distinct  domains,  (a).  α 
(residues 1–150) (b). β (residues 151–287) (c). γ (residues 288–
414) with half life ~ 30 min. It does not exhibit plasmin activity but 
binds to plasminogen in 1:1 ratio and shows plasmin activity [14]. 
Being a prokaryotic protein, it is allied with allergic reactions and 
also  antibody-mediated  inhibition  of  plasminogen  activation. 
Because  of  its  non  fibrin  specific  SK  was  also  associated  with 
bleeding complications and rethrombosis. 
RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR 
A serine protease (tPA) is a fibrin specific thrombolytic molecule 
consisting of 527 amino acids with a molecular weight of 70kDa 
(15).  Tissue  plasminogen  activators  available  in  two  forms  (a). 
single chain form (sct-PA) (b). two chain form (tct- PA). It contains 
four domains (a). A fibronectin type I finger (F) domain with NH2-
terminal region of 47-residues (residue 4 to 50), (b). An epidermal 
growth factor domain (residue 50 to 87), (c) Two kringle domains 
comprising residues from 87 to 176 and from 176 to 262 (K1 and 
K2) (d). A serine proteinase domain (residues 276 to 527) with 
active  site  residues  His  322,  Asp  371  and  Ser  478  [16]. 
Plasminogen activator inhibitor- 1(PAI-1) inhibits the PA activity of 
t-PA [17]. The amino acids at 296-299 in t-PA was associated with 
the inhibition by PAI-1 [18]. In the absence of fibrin, t-PA is a poor 
enzyme to activate the plasminogen. But in the presence of fibrin 
it enhances the plasminogen activation rate. 
Alteplase, a tissue plasminogen activator was produced by r-DNA 
technology. It is synthesized using the cDNA of human melanoma 
cell line [19]. COOL 1 and COOL 2 clinical trail’s demonstrated the 
efficiency and safety of t-PA in the treatment of central venous 
access  device  (CVAD)  occlusion  [20].  In  GUSTO-1,  patients 
treated  with  alteplase  had  a  6.3%  mortality  rate  and  0.72% 
incidence  of  intracranial  haemorrhage  [21].  Compared  with 
streptokinase,  the  second  generation  thrombolytic  molecule, 
alteplase shows 1% drop in death rate or nonfatal stroke. After the 
onset  of  stroke  symptoms,  alteplase  was  given  as  I.V  to  the 
patients within 3 hours and most common and severe side effect 
with alteplase was bleeding. 
APSAC 
Anisoylated  plasminogen-SK  activator  complex  (APSAC)  is  the 
another form of SK. The equimolar acylated complex of human 
lysplasminogen  and  SK  act  on  plasminogen  upon  deacylation 
spontaneously  in  plasma.  Activation  of  anistreplase  to  lys-
plasminogen-streptokinase  was  occurs  by  hydrolytic  process  in 
blood or thrombus. The hydrolytic process results the release of p-
anisoyl group by deacylation. After intra venous administration of 
anistreplase,  a  non-enzymatic  deacylation  process  was  started 
and it converts plasminogen to which the streptokinase is bound 
[17].  On single  bolus  administration,  The  International  Study  of 
Infarct  Survival  (ISIS)-3  showed  a  10.5%  mortality  and  0.6% 
intracranial hemorrhage [22]. The brand name of anistreplase was 
Eminase® and possesses the side effects like streptokinase. 
TENECTEPLASE 
Tenecteplase  is  a  t-PA  mutant  of  alteplase  and  was 
bioengineered to have extended half-life. Asn
117 was substituted 
by  Gln  results  the  deletion  of  glycosylation  site  in  kringle  1 
domain. Substitution of Thr  103 with Asn reintroduces the new 
glycosylation site. Replacement of the amino acids Lys
296 - His
297 - 
Arg
298  -  Arg
299  with  Ala  increases  the  resistance  to  PAI-1.  The 
deletion of carbohydrate chain at Asn
117 prolongs its half-life 17-20 
min. Like native t-PA, tenecteplase also binds to fibrin [23, 24]. 
The  ASSENT-1  (assessment  of  safety  and  efficacy  of  a  new 
thrombolytic  agent)  trial  showed  the  safety  and  efficacy  of 
tenecteplase  [25]  and  ASSENT-2  trails  in  patients  with  acute 
myocardial  infarction  shows  bleeding  and  allergic  reactions 
associated by using this drug [26]. 
RETEPLASE 
Reteplase  (recombinant  plasminogen  activator,  r-PA)  is  a 
derivative of t-PA, consists of 355 amino acids with a molecular 
weight of 39 kDa. It is a unglycosylated protein with single chain 
deletion variant of alteplase expressed by Escherichia coli. Like 
alteplase,  in  the  absence  of  fibrin  it  has  plasminogen  activator 
activity,  but  the  binding  affinity  to  fibrin  is  significantly  (5  fold) 
lower than alteplase [27]. The competence of reteplase in patients 
with acute myocardial infarction has been evaluated by RAPID I 
(recombinant  plasminogen  activator  angiographic  phase  II 
international dose finding study) trial, where it was administrated 
as a double bolus against to the standard dose of alteplase, the 
patency  of  reteplase  was  reached  earlier  and  more  frequently 
than with alteplase. Like alteplase, in the GUSTO (global use of 
strategies to open occluded coronary arteries) III trial the mortality 
rate after 30 days was not significantly different with reteplase as 
a  double  bolus  [28].  Like  other  drugs,  bleeding  and  allergic 
reactions are also associated by using the reteplase. 
All the above mentioned thrombolytics posses some side effects 
mainly bleeding complications and reocclusion. By keeping these 
problems, now – a – days a lot of research is focused on third 
generation molecule staphylokinase. 
STAPHYLOKINASE 
Staphylokinase  is a bacterial protein found in the culture medium 
of many strains of Staphylococcus aureus that converts inactivate 
plasminogen  into  active  proteolytic  enzyme  plasmin  [29,  30] 
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ago  [31].  Davidson  [32]  and  Glanville  [33]  precipitated 
staphylokinase from culture supernatants by adjusting the pH to 
3.3 with 10M - HCl. Glanville precipitated the staphylokinase with 
75 % (NH4)2S04 and it was purified by chromatography on CM-
cellulose  columns  or  by  affinity  chromatography  on  plasmin  – 
Sepharose [34] or on plasminogen – Sepharose [35]. The in vitro 
fibrinolytic  properties  of  staphylokinase  was  evaluated  [36,  37] 
and in vivo thrombolytic properties were studied in dogs [38, 39]. 
Staphylokinase – neutralizing activity was detected by using a clot 
lysis assay [40].  
Staphylokinase gene encodes a total of 163 amino acids, where 
the first 27 amino acids are coding for the signal peptide and from 
amino  acid  28  corresponding  to  the  full-length  mature 
staphylokinase  (mSAK)  [41,  42,  43,  44,  45]  as  a  single 
polypeptide with molecular weight of approximately 15.5 kDa [46] 
and shows no significant homology with streptokinase [47].  
SAK  does  not  have  any  enzymatic  activity  and  activation  of 
plasminogen was performed by two step mechanism [48]. Initially 
formation of complex between SAK and plasmin(ogen). Later the 
SAK  –  plasmin(ogen)  complex  active  site  is  exposed  with  the 
conversion  of  plasminogen  to  plasmin,  thus  SAK  acting  as  a 
potent plasminogen activator. In the initial lag phase, plasminogen 
in  SAK-plasminogen  complex  is  activated  to  plasmin  with  the 
trace  amounts  of  plasmin,  which  later  contaminates  in 
plasminogen  preparation  [49].  The  complex  between 
streptokinase  and  plasminogen  exposes  the  active  site  of 
plasminogen  devoid  of  any  proteolytic  cleavage  [50].  After 
generation  of some  plasmin, SAK  binds  to  plasmin  rather than 
plasminogen  and  then  SAK-plasmin  complex  directly  activates 
plasminogen to plasmin significantly (Figure  – 2). PA activity of 
SAK-plasmin  (ogen)  complex  was  inhibited  by  α2-AP  in  the 
absence of fibrin [51, 52]. The inhibition by α2-AP was suppressed 
by EACA, lysine binding site (LBS) of plasmin in this complex [53] 
and inhibitory effect was reduced in the presence of fibrin or FCB-
2 by competing for interaction with the LBS [54]. The initial rate of 
plasminogen activation by SAK was accelerated two to three folds 
by the addition of fibrin [55]. SAK does not bind to fibrin and the 
enzymatic efficiency of the plasminogen activation by SAK was 
improved 30-fold, 38-fold and 8.5- fold by the (DD)E complex [56]. 
So,  SAK-plasmin(ogen)  complexes  express  fibrin-specific 
plasminogen activation on the surface of fibrin and degrades fibrin 
(Fig – 2). 
The  following  model  was  proposed  for  the  activation  of 
plasminogen (Plg) by staphylokinase (Sak). 
 
Fig    2:  Activation  of  plasminogen  (Plg)  by  staphylokinase 
(Sak) (Source from Blood, 1994, 84: 680-686) 
SAK was highly fibrin specific but having lesser fibrinogenolytic 
properties when compared to streptokinase. Systemic fibrinogen 
degradation,  α2-antiplasmin  consumption,  and  plasminogen 
activation  were  not  found  with  the  use  of  staphylokinase.  The 
plasma half life of staphylokinase was 6.3 min in phase I trials. 
Double-bolus administration was safe when compared to single 
bolus  administration  [57].  In  the  CAPTORS  (Collaborative 
Angiographic Patency Trial of Recombinant Staphylokinase) I and 
II trials the therapeutic potential of SAK and its derivatives has 
been studied and support its therapeutic potential [58, 59]. 
Clinical  results  with  staphylokinase  was  encouraging,  but 
heterologous protein staphylokinase is immunogenic in humans 
and  induces  antibody  formation,  not  possible  to  repeated 
administration  and  its  potency  is  limited  [60].  38%  of  treated 
patients  was  alleged  by  rethrombosis  [61].  To  reduce  the 
immunogenicity  and  prolonged  half-life  of  SAK,  site  directed 
mutagenesis had been done without the considerable loss of their 
fibrinolytic  and  fibrin  specificity.  In  order  to  reduce  the 
immunogenicity  and  prolonged  half-life  of  wild  type  SAK, 
polyethylene  glycol-derivatized  cystein  substitution  variants  of 
recombinant  SAK  (Code  SY161-P5)  was  generated  by 
substitution  of  12  amino  acids  in  SAK  molecule  (K35A,  E65Q, 
K74R, E80A, D82A, T90A, E99D, T101S, E108A, K109A, K130T, 
K135R) reduced antigenicity. 
GENE STRUCTURE OF STAPHYLOKINASE 
A 489 bp sequences of full length staphylokinase encodes signal 
peptide followed by 163 amino acid mature staphylokinase. The 
coding sequence was preceded upstream by canonical Shine – 
Dalgarno  sequence  and  by  -10  and  -35  prokaryotic  promoter 
sequences.  This  136  amino  acid  staphylokinase  shows  no 
significant  homology  with  streptokinase.  The  four  nucleotide 
difference between the coding regions of sakØC, sak42D and sak 
–  STAR  genes  because  of  silent  mutations.  These  affect  the 
codons for amino acids in full length staphylokinase at 38, 61, 63, 
and 70 (in mature staphylokinase 11, 34, 36, and 43) [43, 62, 63, 
64]. The  four  affected  condons  (a)  Amino  acid  38  is  Lys  in  all 
staphylokinase moieties (b) Amino acid 61 is Ser in Sak STAR but 
Gly in SakØC and Sak42D (c) Amino acid 63 is Gly in Sak STAR 
and in SakØC,  but Arg in Sak42D (d) Amino acid 70 is His in 
SakSTAR  and  in  SakØC,  but  Arg  in  Sak42D.  All  the  reported 
sequences were markedly in the 3' region of the staphylokinase 
molecule, approximately 160 nucleotides downstream of the stop 
codon were suggesting that this region is not important for protein 
expression. 
PROTEIN STRUCTURE OF STAPHYLOKINASE 
X-ray scattering, dynamic light scattering, ultracentrifugation, and 
UV circular dichroism spectroscopy revealed the solution structure 
of  staphylokinase.  Radius  of  gyration,  stokes  radius,  maximum 
dimension and sedimentation coefficient was 2.3 nm, 2.12 nm, 10 
nm and 1.71 S respectively indicated the shape of staphylokinase 
is elongated. Sak contains two folded domains of similar size and 
the mean distance of the centers of gravity of the domains is 3.7 
nm.  The  positions  of  the  two  domains  are  variable  in  solution, 
signifying that the molecule is like a flexible dumbbell [65]. Based 
on  sodium  dodecyl  sulfate-polyacrylamide  gel  electrophoresis 
[SDS-PAGE])  and  iso-electric  point  Several  molecular  forms  of 
staphylokinase was purified with different molecular weights [66, 
67, 68]. Low molecular derivatives of mature staphylokinase were 
obtained lacking the 6 or the 10 amino terminal amino acids. In 
buffer  milieu,  on  interaction  with  plasmin(ogen)  mature 
staphylokinase is converted to Sak-Δ10 and it was shown to have 
same fibrinolytic activity like SAK. Amino acid at 26 was useful for 
the activation of plasminogen by staphylokinase, substitution with 
Arg or Val results the loss of functional activity, but substitution 
with Leu or Cys has little or no effect on functional activity [69]. In 
mutant  protein  these  amino  acid  changes  doesn’t  affect  the 
solution structure. Three-dimensional structure of the molecule will 
be required to know these observations at molecular level. 
EXPRESSION OF STAPHYLOKINASE FROM BACTERIA 
With  the  help  of  recombinant  DNA  technology  and  molecular 
techniques, staphylokinase gene was isolated from lysogenically 
converted S. aureus and expressed in non-pathogenic expression 
hosts  E.coli.  The  sak  gene  is  cloned  into  pET-28a+  and 
expressed in an IPTG inducible E.coli BL21 and salt induced E. 
coli GJ1158. The mature recombinant sak protein expressed in 
E.coli is also further extracted and analyzed by different methods 
to demonstrate thrombolytic activity. 
In  Escherichia  coli  BL21  the  expression  of  recombinant 
staphylokinase has led to the formation of inclusion bodies and 
the  final  yield  of  the  protein  was  20  mg/L  [70],  200  mg/L 
fermentation broth [71], 300 mg/L [72], 70 to 500 mg/L [73], 1 g/L 
[74]  and  2.8  g/L  of  fermentation  broth  [75)].  Also,  the  sak 
expression was carried out in different expression host systems 
like E.coli [76, 77, 78], Bacillus subtilis [79], Streptomyces lividans 
[80]. 
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EXPRESSION OF STAPHYLOKINASE FROM YEAST 
Methylotrophic  yeast  Hansenula  polymorpha  provides  an 
alternative expression system and has successfully developed for 
several  commercial  production  of  protein  and  in  vaccine 
production.  The  supernatant  of  fermented  rSAK-1  strain  was 
treated with endoglycosidase H led to removal of the smear-like 
band, while the well-defined band at 16 kDa was non-glycosylated 
rSAK-1. This provided the evidence of rSAK-1 strain secretes both 
glycosylated  and  non-glycosylated  rSAK-1,  while  the  rSAK-2 
strain  secretes  only  nonglycosylated  rSAK-2.  Amino  acid 
sequences of wt-SAK and SAK-variants of rSAK-1 (= THR 174) 
and  rSAK-2  were  shown  below.  The  difference  in  the  primary 
structure  of  the  amino  acid  sequence  of  three  SAK  molecules 
were shown in italics and bold letters indicates the potential N-
linked  glycosylation-site  motif.  Thr-30  was  replaced  with  Ala  in 
rSAK2 strain for nonglycosylated protein [74, 81]. 
wt SAK 
SSSFDKGKYKKGDDASYFEPTGPYLMVNVTGVDSKGNELLSPH
YVEFPIKPGTTLTKEKIEYYVEWALDATAYKEFRVVELDPSAKIE
VTYYDKNKKKEETKSFPITEKGFVVPDLSEHIKNPGFNLITKVVIE
KK 
rSAK1 
SSSFDKGKYKKGDDASYFEPTGPYLMVNVTGVDSKGNELLSPH
YVEFPIKPGTTLTKEKIEYYVDWALDATAYQEFEVVSLSPSAKIE
VTYYDKNKKKEETKSFPITEKGFTVPDLSEHIKNPGFNLITYVVIR
KK 
rSAK-2 
SSSFDKGKYKKGDDASYFEPTGPYLMVNVAGVDSKGNELLSPH
YVEFPIKPGTTLTKEKIEYYVDWALDATAYQEFEVVSLSPSAKIE
VTYYDKNKKKEETKSFPITEKGFTVPDLSEHIKNPGFNLITYVVIR
KK 
The recombinant Pichia carrying multiple insertions of SAK gene 
yielded high-level (~1 g/l) of extracellular glycosylated rSAK (~18 
kDa)  (74).  Addition  of  antibiotic  like  tunicamycin  during  the 
induction  phase  results  the  expression  of  non-glycosylated  and 
highly  active  rSAK  of  ~15  kDa.    Staphylokinase  was  also 
produced  as  heterologous  fusion  protein  in  methanol  inducible 
Pichia pastoris GS115 and has the good fibrinolytic activity [82]. 
STAPHYLOKINASE  WITH  THROMBOLYSIS  AND 
ANTIPLATELET ACTIVITY 
Based  on  site-directed  mutagenesis,  Arg-Gly-Asp  (RGD)  motif 
was engineered in the staphylokinase (SAK). This mutant of SAK 
was  designated  as  RGD-SAK,  was  expressed,  purified  and 
characterized. Biochemical analysis revealed that RGD-SAK has 
similar  structure  and  fibrinolytic  function  like  SAK.  In  in  vitro 
platelet binding activity RGD-SAK has higher affinity with platelets 
than SAK and in vitro platelet-rich clot lysis assay demonstrated 
that  the  engineered  mutant  outperformed  the  non-manipulated 
SAK. Time and the concentration required to obtain 50% platelet 
rich clot lysis (C50) were reduced significantly when using different 
concentrations of RGD-SAK compared with SAK. RGD-SAK was 
found to inhibit ADP-induced platelet aggregation where the SAK 
had negligible effect on platelet aggregation. RGD-SAK had the 
dual function to target the platelet-rich clots and to block platelets 
aggregation. It may serve as a more potential thrombolytic agent 
with  platelet-targeted  thrombolytic  and  antiplatelet  aggregation 
activities in compared with SAK. Addition of RGD may decrease 
the rethrombosis. Table 1: revealed the Km and Kcat of both SAK 
and RGD-SAK. 
Table 1: Kinetics of equimolar mixture of human plasmin with 
RGD-SAK. 
Thromolytic 
agent  Km (μM)  Kcat (s
-1)  Kcat/Km  (μM
-
1s
-1) 
SAK  0.39  ± 
0.03 
0.015  ± 
0.002 
0.033  ± 
0.003 
RGD-SAK  0.78  ± 
0.05 
0.031  ± 
0.001 
0.037  ± 
0.005 
SAK VARINATS 
Recombinant RGD-hirudin by fusing the tripeptide RGD sequence 
to the native hirudin (wt-hirudin) and was expressed at high levels 
in  Pichia  pastoris  [83].  The  anti-thrombin  activity  of  purified 
recombinant  RGD-hirudin  and  sak-hirudin  was  12,000  ATU/mg, 
which  is  equivalent  to  native  –  hirudin,  but  r-RGD-hirudin  only 
inhibit platelet aggregation. The biological effects of r-RGD-hirudin 
and r-sak-hirudin on Thrombin Time (TT), Prothrombin Time (PT), 
Activated  Partial  Thromboplastin  Time  (APTT),  Bleeding  Time 
(BT),  maximum  platelet  aggregation  (PAGm)  induced  by  ADP 
were  studied  in  animal  models  and  compared  with  that  of  wt-
hirudin.  r-sak-hirudin  and  r-RGD-hirudin  was  three  times  more 
effective in contrast to wt-hirudin in preventing thrombosis. The 
animals were infused r-RGD-hirudin had prolonged TT, PT, and 
APTT which were similar to that of wt-hirudin; but only r-RGD-
hirudin was capable of inhibiting PAGm.  
Different methods of statistical optimization  were carried out on 
different  media  components  concentration  for  enhanced 
production  of  sak  variants  having  maximum  fibrinolytic  activity 
[84]. 
CHIMERIC MULTIFUNCTIONAL STAPHYLOKINASE 
Chimeric  staphylokinse  was  created  by  cross  linkage  of 
staphylokinase with hirudin to antifibrin and antiplatelet antibodies. 
Now a days, research studies proved that activated platelets play 
a  key  role  in  arterial  thrombosis  and  rethrombosis.  After 
thrombolytic  therapy  the  secondary  clots  were  formed  by  the 
action of platelet aggregation [85]. RGD tripeptide can recognize 
the  platelet  membrane  glycoprotein  IIb/IIIa  (GPIIb/IIIa)  receptor 
and  binding  of  surface  glycoprotein  GPIIb/IIIa  to  fibrinogen 
mediates  platelet  aggregation  and  RGD  prevents  fibrinogen 
binding to GPIIb/IIIa on activated platelets, thus inhibiting platelets 
aggregation activity [86]. It indicates the clot lysis efficacy of SAK 
can  be  dramatically  enhanced  with  the  ability  of  direct  active 
platelet binding and rethrombosis complication can be minimized 
with antiplatelet aggregation. 
Several  chimeric  proteins  have  been  produced  based  on  the 
attempts  to  combine  the  advantages  of  staphylokinase  with 
thrombin  inhibitor  and  Platelet  aggregation  inhibitor  to  prevent 
reocculusion. Hirudin was selected as antithrombin partner due to 
its compatibility with the host secretion system. A model fusion 
protein  was  constructed  by  fusing  the  small  functional  domain 
hirudin variant (HV1) in both N- and C- terminals of sak results the 
HV1-SAK and SAK-HVI. Plasminogen activation of SAK was not 
altered by the addition of molecules at N- terminal or C- terminal 
sequences. But at N- terminal cleavage with lysines results the 
unstable  fusion.  However,  C-  terminal  fusions  represent  stable 
configuration  for  rational  development  of  improved  thrombolytic 
agents based on SAK [87]. 
SAK and hirudin  were joined together via a  pair of engineered 
coiled sequences that act as the hetero dimerization domain. A 
lysine rich coiled coil sequence (K-coil) is added to the C-terminal 
tail  of  SAK to  generate  SAK-K coil  (SAKK).  Glutamic  acid  rich 
coiled coil sequence  (E-coil) is added  to  the  C-terminal  end  of 
hirudin  to  generate  hirudin-E.  Coli  (HE).  These  heterodimeric 
molecule  (HE-SAKK)  is  a  superior  thrombolytic  agent  in 
comparison to staphylokinase as confirmed by in vitro fibrin and 
plasma clot lysis studies [88]. Site directed mutagenesis at K35 
was  substituted  with  Arg  (R)  and  results  in  novel  SAK  variant 
RGD-SAK  has  higher  affinity  with  platelets  than  SAK  and 
possesses  thrombolytic  activity  and  ADP-induced  platelet 
aggregation in a dose dependent manner [89]. PLATSAK(Platelet-
Anti-thrombin-Staphylokinase) was designed which include three 
inhibitory regions RGD sequence, a part of fibrinopeptide A, an 
inhibitor of thrombin and the C- terminal of hirudin a direct anti-
thrombin [90].  
In  an  another  approach  of  improvement  of  the  thrombolytic 
potential of SAK, as well as to introduction of antithrombotic and 
antiplatelet activity, the recombinant SAK-RGD-K2-Hir and RGD-
K2-Hir-SAK  were  constructed  which  were  the  more  potent  and 
fast acting thrombolytic agent as compared with standard r-SAK 
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CONCLUSION 
Thrombolytic  therapy  remarkably  reduces  the  mortality  and 
morbidity caused by acute myocardial infarction and also used in 
the treatment of various other thromboembolic disorders. Because 
of the complication while in use i.e bleeding, fibrin specificity and 
reocclussion,  researchers  focussed  their  attention  on  third 
generation  thrombolytic  molecule  with  minimal  side  effects. 
Patients  will  fail  to  achieve  and  complete  reperfusion  with  the 
current  regimens.  For  improved  efficacy  and  safety  profile, 
genetically engineered 'third generation' thrombolytic agents are 
improved clinical and also the opportunity to determine the relative 
importance of fibrin specificity, plasma half-life, and resistance to 
inhibition by plasma inhibitors in thrombolytic therapy. In addition 
antibody targeted plasminogen activators and antithrombin agents 
are  in  use  to  construct  the  thrombolytic  variants.  However,  the 
optimal thrombolytic strategy has yet to be determined which have 
the capability of ~100% reperfusion and without complications like 
bleeding and reocclusion. In depth research studies are going to 
develop the perfect thrombolytic agents devoid of side effects. 
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